Localised prostate cancer
What is localised prostate cancer?
Localised prostate cancer is cancer that’s inside the prostate and hasn’t spread to other parts of the body. You may also hear it called early or organ-confined prostate cancer, or stage T1 or T2 prostate cancer.
Most localised prostate cancer grows slowly – or doesn’t grow at all – and has a low risk of spreading. So it may never cause you any problems or affect how long you live. Because of this, localised prostate cancer might not need treatment. You might be able to have your cancer monitored with regular check-ups instead. This is to make sure the cancer isn’t growing more quickly than expected.
But some men will have cancer that grows quickly and has a high risk of spreading. This is more likely to cause problems and needs treatment to stop it spreading outside the prostate.
What do my test results mean?
Your results will help your doctor understand how quickly your cancer might grow and whether it has spread. This will help you and your doctor to discuss what treatments might be suitable for you.
Read more about what your test results might mean.
What are my treatment options?
Most localised prostate cancer often grows slowly and might not need treatment. You may be able to have your cancer monitored with regular check-ups instead. If you decide to have treatment, it will usually aim to get rid of the cancer.
The two ways of monitoring localised prostate cancer are:
Treatments for localised prostate cancer include:
hormone therapy (usually given alongside your main treatment).
Newer types of hormone therapy known as androgen receptor pathway inhibitors (ARPIs) may be an option for some men with localised prostate cancer that has a high risk of spreading.
You might also be offered high-intensity focused ultrasound (HIFU) or cryotherapy, types of focal therapy but they are less common and only available in specialist centres in the UK or as part of a clinical trial.
Your doctor or nurse will talk you through your treatment options and help you choose the right type of monitoring or treatment for you. You might not be able to have all of the treatments listed. There’s no overall best treatment for localised prostate cancer, and each one has its own advantages and disadvantages. Read more about choosing a treatment.
What will happen after my treatment?
You will have regular check-ups during and after your treatment to check how well it is working. You may hear them called follow-up appointments. You’ll have regular PSA blood tests – ask the people treating you how often you’ll have these. If your PSA level goes down this usually suggests your treatment is working.
Tell your doctor or nurse about any side effects you’re getting. There are usually ways to manage side effects.
Make sure you have the details of someone to contact if you have any questions or concerns between check-ups. This might be your specialist nurse or key worker. You can also speak to our Specialist Nurses.
Read more about follow-up after prostate cancer treatments.
What is my outlook?
Many men will want to know how successful their treatment is likely to be. This is sometimes called your outlook or prognosis. No one can tell you exactly what will happen, as it will depend on many things, such as the stage of your prostate cancer and how quickly it might grow, your CPG (Cambridge Prognostic Group) your age, and any other health problems. Speak to your doctor about your own situation.
Most localised prostate cancer is slow-growing and may not need treatment or shorten a man’s life. For many men who have treatment for localised prostate cancer, the treatment will get rid of the cancer. For some men, treatment may be less successful and the cancer may come back. If this happens, you might need further treatment.
For more information about the outlook for men with prostate cancer, visit Cancer Research UK. The figures they provide are a general guide and they cannot tell you exactly what will happen to you. Speak to your doctor or nurse about your own situation.
Where can I get support?
Being diagnosed and living with prostate cancer can change how you feel about yourself and your life. You may be feeling scared, overwhelmed, low or even angry. There is no 'right' way to feel and everyone reacts differently. Its important to remember that support is available, and you don't have to fact this alone.
Visit our wellbeing hub for information to help support you in looking after your emotional, mental, and physical wellbeing. You can also find out more about our support services and chose what works for you.
If you are close to someone with prostate cancer, find out more about how you can support someone with prostate cancer and where to get more information.
Questions to ask your doctor or nurse
What is my Gleason score and stage of my cancer?
What is my CPG (Cambridge Prognostic Group) score?
What treatments are suitable for me? Could my cancer be monitored instead?
How quickly do I need to make a decision about treatment?
Can I join any clinical trials?
What are the advantages and disadvantages of each treatment? What are the side effects?
Are all of the treatments available at my local hospital? If not, how could I have them?
Can I see the results of treatments you’ve carried out?
Can I get copies of all my test results and letters about my treatment?
If I have any questions or get any new symptoms, who should I contact?
References and reviewers
Updated: October 2026｜To be reviewed: October 2027
Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet. 2017 Jan. doi:10.1016/S0140-6736(16)32401-1
Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. Jama. 2005;293(17):2095–101.
Andersen MF, Midtgaard J, Bjerre ED. Do Patients with Prostate Cancer Benefit from Exercise Interventions? A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022 Jan 15;19(2):972. doi:10.3390/ijerph19020972
Berney DM. The case for modifying the Gleason grading system. BJU Int. 2007;100(4):725–6.
British Medical Association. Patients recording consultations [Internet]. [cited 2026 Oct 26]. Available from: https://www.bma.org.uk/advice-and-support/ethics/confidentiality-and-health-records/patients-recording-consultations
Cornford P, Tilki D, van der Bergh RCN, Eberli D, Fonteyne V, Gandaglia G, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer [Internet]. 2026 [cited 2026 Mar 23]. Available from: https://uroweb.org/guidelines/prostate-cancer
Cornu JN, Elterman D, Hashim H, Herrmann .R.W, Karavitakis M, Malde S. EAU Guidelines on the Management of Non-neurogenic Male LUTS [Internet]. EAU; 2026 [cited 2026 Aug 11]. Available from: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts
Dovey Z, Horowitz A, Waingankar N. The influence of lifestyle changes (diet, exercise and stress reduction) on prostate cancer tumour biology and patient outcomes: A systematic review. BJUI Compass. 2023 Jul;4(4):385–416. doi:10.1002/bco2.237 PubMed PMID: 37334023; PubMed Central PMCID: PMC10268595.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52
Hamblen AJ, Bray JW, Hingorani M, Saxton JM. Physical activity and dietary considerations for prostate cancer patients: future research directions. Proc Nutr Soc. 2023 Sep;82(3):298–304. doi:10.1017/S0029665123000046
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016 Sep 14. doi:10.1056/NEJMoa1606220
Hegarty J, Walsh E, Harry Comber, Tony Fitzgerald, Kazer MW. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev. 2010.
Humphrey P, Moch H, Cubilla A, Reuter V, Ulbright T. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and BladderTumours [Internet]. 2016. Available from: http://www.europeanurology.com/article/S0302-2838%2816%2900205-0/abstract/the-2016-who-classification-of-tumours-of-the-urinary-system-and-male-genital-organs-part-b-prostate-and-bladder-tumours
Johnson EE, Mamoulakis C, Stoniute A, Omar MI, Sinha S. Conservative interventions for managing urinary incontinence after prostate surgery. Cochrane Database Syst Rev. 2023;2023(4). doi:10.1002/14651858.cd014799.pub2
Lee A. Radiation Therapy Combined With Hormone Therapy for Prostate Cancer. Semin Radiat Oncol. 2006 Jan;16(1):20–8. doi:10.1016/j.semradonc.2005.08.003
National Institute for Health and Care Excellence. Low dose rate brachytherapy for localised prostate cancer. Interventional procedure guidance 132. 2005.
National Institute for Health and Care Excellence. Patient experience in adult NHS services: improving the experience of care for people using adult NHS services. 2021.
National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management [Internet]. 2021 [cited 2022 Dec 19]. Available from: https://www.nice.org.uk/guidance/ng131
National Institute for Health and Clinical Excellence. High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer. Interventional procedure guidance 174. 2006.
Nguyen DD, Berlin A, Matthew AG, Perlis N, Elterman DS. Sexual function and rehabilitation after radiation therapy for prostate cancer: a review. Int J Impot Res. 2021 May;33(4):410–7. doi:10.1038/s41443-020-00389-1
NHS England. Clinical Commissioning Policy: Brachytherapy dose escalation with external beam radiotherapy for intermediate- and high-risk localised prostate cancer (adults) [Internet]. NHS England; 2021 [cited 2023 Mar 2]. Available from: https://www.england.nhs.uk/wp-content/uploads/2021/07/1831-Policy-for-publication-Final.pdf
NHS. nhs.uk [Internet]. 2024 [cited 2026 Oct 26]. Rectal examination. Available from: https://www.nhs.uk/tests-and-treatments/rectal-examination
NHS. nhs.uk [Internet]. 2025 [cited 2026 Oct 26]. Treatment for prostate cancer. Available from: https://www.nhs.uk/conditions/prostate-cancer/treatment
NHS. nhs.uk [Internet]. 2024 [cited 2026 Oct 26]. PSA test. Available from: https://www.nhs.uk/tests-and-treatments/psa-test/
NICE. How should I assess a person with suspected prostate cancer? [Internet]. 2026 [cited 2026 Oct 10]. Available from: https://cks.nice.org.uk/topics/prostate-cancer/diagnosis/assessment/
Razdan S, Pandav K, Altschuler J, Moody K, Martin L, Patel HD, et al. Impact of exercise on continence in prostate cancer patients post robotic assisted radical prostatectomy: a systematic review. Am J Clin Exp Urol. 2023;11(4):320–7. PubMed PMID: 37645610; PubMed Central PMCID: PMC10461030.
Ruane-McAteer E, Porter S, O’sullivan JM, Santin O, Prue G. Active surveillance for favorable-risk prostate cancer: Is there a greater psychological impact than previously thought? A systematic, mixed studies literature review. Psychooncology. 2017;26(10):1411–21.
Wang L, Wu L, Qian C, Ju Y, Liu T, Chen Y, et al. The Beneficial Effect of a Healthy Dietary Pattern on Androgen Deprivation Therapy-Related Metabolic Abnormalities in Patients with Prostate Cancer: A Meta-Analysis Based on Randomized Controlled Trials and Systematic Review. Metabolites. 2022 Oct 13;12(10):969. doi:10.3390/metabo12100969
Wedlake LJ. Nutritional strategies to prevent gastrointestinal toxicity during pelvic radiotherapy. Proc Nutr Soc. 2018 Nov;77(4):357–68. doi:10.1017/s0029665118000101
Yuan F, Wang Y, Xiao X, Zhang X, Jing M, Kamecki H, et al. A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy. Transl Androl Urol. 2023 Aug 31;12(8):8. doi:10.21037/tau-23-272
This webpage was reviewed and updated by:
Our Specialist Nurses
